- Trial phase
- Approved / marketed (per public record, could not be re-verified via web this session; no approval row in local FDA tab
- Time to market
- Already on the market (reported); no new approval timeline applies.
- Why 3/10
- No hard, dated OPSYNVI-specific catalyst (PDUFA, pivotal readout, or label decision) is scheduled in the next ~12 months in any source retrievable this session, and as an already-marketed drug inside a ~$600B mega-cap the defining binary has passed, so the score is capped at the approved/no-pending-decision band and set at 3 because OPSYNVI is a tiny share of JNJ's value.
For a JNJ shareholder, OPSYNVI is not a trade, it has no dated binary in the next 12 months and is a rounding error inside a ~$600B market cap, so any single-product news would barely move the stock. Watch quarterly filings for PAH revenue commentary and the competitive ralinepag/sotatercept readouts for class-level context; investors who want a PAH-specific catalyst should look at smaller single-asset developers instead.
Price Chart
Executive Summary
OPSYNVI is the brand name for a fixed-dose combination of macitentan (an endothelin receptor antagonist) plus tadalafil (a PDE5 inhibitor), one daily pill combining two established drug classes used to lower blood pressure in the lungs in pulmonary arterial hypertension (PAH). It is marketed by Johnson & Johnson (JNJ), and the filing hint checks out: JNJ is verified as JOHNSON & JOHNSON (NYSE, pharma), and local FDA/trial data confirm macitentan is a J&J/Actelion PAH franchise drug with completed Phase 3 pediatric PAH trials and already-genericized competition. Net investor read: a real but niche product inside a diversified mega-cap with no near-term binary; nothing to trade on by itself.
How It Works
PAH is high blood pressure in the arteries of the lungs, which strains the right side of the heart. OPSYNVI packs two oral medicines into one pill: macitentan, an "endothelin receptor antagonist" that blocks a signaling protein that narrows lung blood vessels, and tadalafil, a "PDE5 inhibitor" that helps the vessel walls relax and widen. Both effects reduce lung blood pressure. Local FDA data this session confirm macitentan's class and use (endothelin receptor antagonist, oral, PAH) and its embryo-fetal toxicity warning; J&J (Janssen/Actelion) sponsors macitentan PAH trials.
Trial Status
No OPSYNVI-specific trial or approval record exists in SecBot's local FDA-action, catalyst, or trial tables. Corroborating evidence: J&J's macitentan franchise is mature, completed Phase 3 pediatric PAH trials (NCT05167825, NCT02932410) and FDA safety-labeling actions for generic macitentan from Apotex, Aurobindo and Zydus, indicating the single-agent ERA is already off patent.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for OPSYNVI in local data, watch J&J quarterly earnings/filings for PAH portfolio commentary.
- Competitive PAH readouts (e.g., United Therapeutics' ralinepag Phase 3 results) could shift market-share expectations for the whole PAH drug class.
- J&J Innovative Medicine leadership transition (Taubert retirement, Cavanaugh succession effective Sept 1, 2026) may signal portfolio priorities.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report